Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06227117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 19, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: 160 to 120 Study description shortened, about 2 words · Study title shortened, about 2 wordsv3 Show 2 more changesShow less
    • Study description shortened, about 2 words
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 2024 to Jul 27, 2023 · Site details revised at 5 of 5 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Jan 2024 to Jul 27, 2023
    • Site details revised at 5 of 5 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer
Trial Details
NCT Number NCT06227117
Lead Sponsor RemeGen Co., Ltd.
Conditions Breast Cancer
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov